Biologically Focused Therapy of Treatment-Refractory MDS Patients

This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Eligibility


Inclusion Criteria:

   - Provide informed consent;

   - Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN
   with >= 5% blasts in the bone marrow or peripheral blood, including chronic
   myelomonocytic leukemia (CMML) 1 and 2 by WHO classification

   - Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating
   agent therapy

   - Cytogenetics reported

Exclusion Criteria:

   - Hypoplastic MDS

   - Patients without adequate marrow samples for ex vivo analysis

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jack Taw
650-723-2781
Not Recruiting

Explore Related Trials

All Stanford Trials

Our research team includes physicians, residents, medical students, research assistants, and volunteers. Our research topics include medical imaging, device validation,  mobile application development, and pharmaceutical trials.  

Some of the Neuro-Opthalmic concerns we investigate include Multiple Sclerosis, Optic Neuritis, IIH, and ICP.